Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6DT9Z)

• Drug Name: S-Ethyl-N-Phenyl-Isothiourea Drug Info
• Synonyms: S-ETHYL-N-PHENYL-ISOTHIOUREA; 19801-34-4; 2-ETHYL-1-PHENYL-ISOTHIOUREA; S-Ethyl N-Phenylisothiourea; CHEMBL451666; Carbamimidothioic acid,N-phenyl-, ethyl ester; CHEMBL545673; S-Ethyl N-Phenylisothio Urea; S-ethyl-N-phenylisothiourea; AC1L87NW; 1-Phenyl-2-ethylisothiourea; SCHEMBL1387773; CTK4E2382; ethyl N'-phenylimidothiocarbamate; ethyl N'-phenylcarbamimidothioate; DTXSID00324314; LAXNJIWNBHHMDO-UHFFFAOYSA-N; ZINC6001367; FCH829155; BDBM50058459; 2-Ethyl-1-phenyl-2-thio-pseudourea; N-phenyl(ethylsulfanyl)methanimidamide

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 347590
  CAS Number: CAS 19801-34-4
  TTD Drug ID: DM6DT9Z

Molecule-Related Drug Atlas

Drug(s) Targeting Nitric-oxide synthase endothelial (NOS3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tilarginine acetate	DMZBGI8	Myocardial infarction	BA41-BA43	Phase 3	[2]
L-NAME	DM01SR6	Hypertension	BA00-BA04	Phase 2	[3]
ACCLAIM	DM0FGDO	Angina pectoris	BA40	Phase 2	[4]
VAS-203	DMKU93J	Brain injury	NA07.Z	Phase 2	[5]
MTR105	DMT0K4F	Hypotension	BA20-BA21	Phase 2	[6]
Autologous cell based gene therapy	DMQA1VT	Pulmonary hypertension	BB01	Phase 1	[7]
L-NIL	DM6Y49D	N. A.	N. A.	Terminated	[8]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[9]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[9]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[1]

Drug(s) Targeting Nitric-oxide synthase brain (NOS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[10]
NXN-462	DMWVBS2	Headache	8A80-8A84	Phase 2	[11]
L-NIL	DM6Y49D	N. A.	N. A.	Terminated	[8]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[9]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[9]
Flavin-Adenine Dinucleotide	DM5S4GK	Discovery agent	N.A.	Investigative	[9]
Heme	DMGC287	Discovery agent	N.A.	Investigative	[1]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[9]
2'-Monophosphoadenosine 5'-Diphosphoribose	DME9S8M	Discovery agent	N.A.	Investigative	[9]
6-isobutyl-4-methylpyridin-2-amine	DM2XB68	Discovery agent	N.A.	Investigative	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nitric-oxide synthase brain (NOS1)	TTZUFI5	NOS1_HUMAN	Inhibitor	[1]
Nitric-oxide synthase endothelial (NOS3)	TTCM4B3	NOS3_HUMAN	Inhibitor	[1]

References

• [1] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [2] Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007 Apr 18;297(15):1657-66.
• [3] Counter-regulation by atorvastatin of gene modulations induced by L-NAME hypertension is associated with vascular protection. Vascul Pharmacol. 2009 Oct;51(4):253-61.
• [4] CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
• [5] Nitric oxide synthase inhibition with the antipterin VAS203 improves outcome in moderate and severe traumatic brain injury: a placebo-controlled randomized Phase IIa trial (NOSTRA). J Neurotrauma. 2014 Oct 1;31(19):1599-606.
• [6] Nitric oxide synthase inhibitor (MTR-105) during open-heart surgery. A pilot double-blind placebo-controlled study of hemodynamic effects and safety. Cardiology. 2008;111(3):181-7.
• [7] Feasibility of using autologous transplantation to evaluate hematopoietic stem cell-based gene therapy strategies in transgenic mouse models of human disease. Mol Ther. 2002 Sep;6(3):422-8.
• [8] Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg Med Chem Lett. 2008 Jan 1;18(1):336-43.
• [9] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] ClinicalTrials.gov (NCT01748877) Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia. U.S. National Institutes of Health.
• [12] Design and synthesis of 2-amino-4-methylpyridine analogues as inhibitors for inducible nitric oxide synthase and in vivo evaluation of [18F]6-(2-fl... J Med Chem. 2009 Apr 23;52(8):2443-53.